About Dihexa
A synthetic hexapeptide analog of angiotensin IV, developed by Harding et al. at Washington State University. One animal study showed potent neurotrophic effects (claimed 10 million times more potent than BDNF in promoting synaptogenesis in vitro). Zero human studies of any kind — no RCTs, no pharmacokinetic data, no safety data in humans. This is the least-studied peptide commonly sold as a supplement. The complete absence of human safety data makes it a significant unknown risk. Sold as a 'research chemical' only.
What Dihexa supports
- One animal neurotrophic study — zero human studies of any kind
- No human safety data exists; significant unknown risk
How much Dihexa to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
10–50
mg
Supplement doses range 10–50 mg. No human studies of any kind exist. Animal studies use very low injection doses. Safety profile in humans is completely unknown.
Clinical evidence
Limited clinical evidence. Zero human studies — not even basic safety data. One animal study only. The least evidence-backed peptide commonly sold as a supplement.
NIH Fact Sheet